Bayer AG

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bayer AG engages in the business of life science fields of healthcare and nutrition. It operates through the following segments: Crop Science, Pharmaceuticals, and Consumer Health. The Crop Science segment includes developing, producing, and marketing products in seeds and plant traits, crop protection, digital solutions, and customer services to promote sustainable agriculture. The Pharmaceuticals segment is involved in prescription products especially for cardiology and women’s health; specialty therapeutics in the areas of oncology, hematology, ophthalmology, and cell and gene therapy; diagnostic imaging equipment; and necessary contrast agents. The Consumer Health segment focuses on non-prescription products in the dermatology, nutritional supplements, digestive health, allergy, cough and cold, and pain and cardiovascular risk prevention categories. The company was founded by Friedrich Bayer and Johann Friedrich Westkott on August 1, 1863 and is headquartered in Leverkusen, Germany.

Bayer AG: Betting On Volatility Expansion

Exclusive agreement with Bayer to evaluate MustGrow's technologies to determine commercial potential.Bayer has the option to acquire exclusive rights to MustGrow's technologies for preplant soil fumigation, bioherbicide applications and postharvest food preservation of potatoes including sprout inhibition in the regions of Europe, Asia Pacific, Middle East and Africa. Bayer will fund and drive all laboratory, field development, regulatory work and market development.Saskatoon, Saskatchewan--(Newsfile Corp. - January 21, 2022) - MustGrow Biologics Corp. (CSE: MGRO) (OTCQB:...

MustGrow and Bayer sign Exclusive Agreement to Develop Sustainable Organic Biologicals in Europe, Asia Pacific, Middle East and Africa

BERLIN & BRISBANE, Calif.--(BUSINESS WIRE)-- #Bayer--Mammoth Biosciences partners with Bayer to develop gene-editing therapies for five in vivo indications, first focusing on liver-targeted diseases.

Bayer and Mammoth Biosciences to Collaborate on Novel Gene Editing Technology

Investors are set to demand around 2.2 billion euros ($2.5 billion) from Bayer as part of a possible class action lawsuit in Germany over the takeover of U.S. seed manufacturer Monsanto, WirtschaftsWoche reported on Monday.

Investors want $2.5 billion in class action over Bayer's Monsanto deal-report

Bayer faces a billion-dollar investor class action lawsuit in Germany over the takeover of U.S. seed manufacturer Monsanto, specialist law firm Tilp Rechtsanwaltsgesellschaft said on Wednesday.

Bayer faces class action suit over Monsanto takeover in Germany, law firm says

The U.S. Supreme Court on Monday asked President Joe Biden's administration for its views on whether the justices should hear Bayer AG's bid to dismiss claims by customers who contend its Roundup weedkiller causes cancer, as the company seeks to avoid potentially billions of dollars in damages.

Supreme Court asks U.S. government for views on Bayer weedkiller case

A California jury found that Bayer's Roundup weedkiller was not the cause of a woman's non-Hodgkin's lymphoma, Bayer said on Thursday, delivering the chemical giant its second trial victory over claims the popular herbicide causes cancer.

Bayer wins second straight verdict in a Roundup cancer case

MONHEIM, Germany--(BUSINESS WIRE)--Today, Bayer, Bushel and Amazon Web Services (AWS) unveiled Project Carbonview. This has been conceptualized by Bayer Crop Science and developed in collaboration with Bushel and AWS. It is a first-of-its-kind technology solution that will help farmers in the United States drive more sustainable supply chains and mitigate the impact agriculture has on the environment by aggregating the carbon footprint of end products. Project Carbonview is the latest example o

Bayer to Launch Project Carbonview, an Industry-First Digital Carbon Footprint Measurement Solution for Agriculture

Bayer's (BAYRY) phase III study evaluating Nubeqa in combination with docetaxel and androgen deprivation therapy for treating metastatic hormone-sensitive prostate cancer meets the primary endpoint.

Bayer's (BAYRY) Phase III Study on Nubeqa Combo Meets Goal

Recursion Pharmaceuticals Inc (NASDAQ: RXRX) expanded its existing strategic collaboration in fibrosis with Bayer AG (OTC: BAYRY).  The expanded collaboration will include Recursion's inferential search capabilities based on its growing maps of human cellular biology.

Recursion, Bayer Expand Fibrosis Pact To Include Inferential Search Capabilities

Bayer AG (OTC: BAYRY) said a combination therapy, including its Nubeqa drug, was shown to prolong the lives of men who have metastatic prostate cancer in a clinical study. Nubeqa (darolutamide) improved overall survival in combination with standard care compared to standard care alone, which was the trial's primary goal.

Bayer's Nubeqa Shows Prolonged Survival In Late-Stage Prostate Cancer Trial

WHIPPANY, N.J.--(BUSINESS WIRE)--The Phase III ARASENS trial investigating the use of the oral androgen receptor inhibitor (ARi) NUBEQA® (darolutamide) in metastatic hormone-sensitive prostate cancer (mHSPC) has met its primary endpoint. In the ARASENS trial, NUBEQA in combination with docetaxel and androgen deprivation therapy (ADT) significantly increased overall survival (OS) compared to docetaxel and ADT. The overall incidence of reported adverse events was similar between treatment arms. D

Phase III Investigational Trial of NUBEQA® (darolutamide) in Combination with Docetaxel and Androgen Deprivation Therapy (ADT) Meets Primary Endpoint of Significantly Increasing Overall Survival (OS) in Patients with mHSPC

BASEL, Switzerland--(BUSINESS WIRE)--Bayer Invests €100 million in Sustainable Health Products to Advance Company's 2030 Sustainability Commitments

Bayer Invests €100 million in Sustainable Health Products to Advance Company's 2030 Sustainability Commitments

Bristol-Myers

British American Tobacco

Imperial Brands PLC

Intel

Merck

Roche Holding AG

Sanofi

Western Union

Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating).

Wide-Moat Stocks On Sale - The December 2021 Heat Map

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer presented new analyses of data from the comprehensive Phase III finerenone clinical trial program, which analyzed KERENDIA® (finerenone) – the first nonsteroidal mineralocorticoid receptor antagonist (MRA)2,3 – versus placebo and in addition to standard of care on cardiovascular (CV) outcomes, including hospitalization for heart failure (HF), across a spectrum of chronic kidney disease (CKD) severity in patients with type 2 diabetes (T2D).1,4 Data from the

Bayer Presented New Analyses Investigating KERENDIA® (finerenone) on Cardiovascular Outcomes in Patients With Chronic Kidney Disease Associated With Type 2 Diabetes

German drugs and pesticides maker Bayer has no plans to split its three main businesses into separately traded companies, Chief Executive Werner Baumann said, amid a flurry of conglomerates moving to break themselves up.

Breaking up is not for us, Bayer CEO says

Microsoft

Microsoft Corp (NASDAQ: MSFT) and Bayer AG (OTC: BAYRY) (OTC: BAYZF) collaborated on new internet-based products aimed at helping farmers and industries tied to agriculture. The financial terms of the arrangement remain undisclosed.

Microsoft, Bayer Collaborate To Develop Digital Agricultural Tools, Capabilities

MONHEIM, Germany--(BUSINESS WIRE)--Today, Bayer announced a strategic partnership with Microsoft to build a new cloud-based set of digital tools and data science solutions for use in agriculture and adjacent industries, bringing new infrastructure and foundational capabilities to accelerate innovation, boost efficiency and support sustainability across value chains. Agriculture and agribusinesses today benefit from a wide range of digital tools and data-powered insights through platforms like B

Bayer, Microsoft Enter Into Strategic Partnership to Optimize and Advance Digital Capabilities for Food, Feed, Fuel, Fiber Value Chain

Amazon

AstraZeneca

Alphabet

Recursion Pharmaceuticals

Narrow AI is trained to solve problems and adapt to change using the concept of machine learning. AI algorithms analyse previous actions and can autonomously improve when given new datasets. AI can analyse vast quantities of data, allowing it to identify patterns in datasets that are too complex for humans to discern.

Artificial Intelligence In Drug Discovery

ST. LOUIS--(BUSINESS WIRE)--Harvest is a time for North American farmers to reflect on the past season's successes and challenges, while looking ahead to what's next. Bayer – with No. 1 market positions in corn, soybean and cotton acres in the U.S. – is also excited about the future and the next round of cutting-edge technologies for growers in 2022 and beyond. Among Bayer's milestones during the 2021 season: XtendFlex® Soybeans Launch: As Bayer's second major soybean trait launch in the last f

Bayer Focuses on Farmers and Drives Innovation into 2022

Investing in Bayer isn't for the faint-hearted given the company's recent and likely future valuation and earnings volatility. However, beneath the hood there's a qualitative company with superb fundamentals and an excellent portfolio.

Bayer - Cheap Again, Plenty Of Volatility, But Still A 'Buy'

Werner Enterprises

Bayer Aktiengesellschaft (BAYZF) CEO Werner Baumann on Q3 2021 Results - Earnings Call Transcript

Bayer's (BAYRY) earnings in the third quarter of 2021 beat estimates. Revenues surge year over year.

Bayer's (BAYRY) Q3 Earnings Beat Estimates, Revenues Rise Y/Y

German pharmaceutical-and-chemical conglomerate Bayer AG on Tuesday swung to a profit for the third quarter and said sales rose, driven by a recovery in its agriculture business.

Bayer swings to a profit as sales rise and adjusts outlook

LEVERKUSEN, Germany--(BUSINESS WIRE)--The Supervisory Board of Bayer AG has appointed Rodrigo Santos (48) to the company's Board of Management and the position of President of the Crop Science division, effective January 1, 2022. Santos will succeed Liam Condon (53), who has informed the Supervisory Board that, in order to pursue career opportunities outside of Bayer, he wishes to bring forward the end date of his contract with the company from December 31, 2023 to December 31, 2021. Santos is

News for Bayer AG Stock (BAYRY)